Clinical Trial

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Study acronym: MUSCAT
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.
Trial Details
NCT Number NCT07321093
Lead Sponsor Biocad
Conditions Relapsing-remitting Multiple Sclerosis (RRMS)
Enrollment 292 participants
Start Date 2025-11-01
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-06